The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.
In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy.
ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.
A controversial HHS document supporting RFK Jr.'s rollback of COVID vaccine guidance relies on disputed or misrepresented science, prompting outrage from health experts who call it “willful medical disinformation.”
A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.
A retrospective study comparing endoscopic and traditional open sinus surgery for chronic rhinosinusitis with nasal polyps found shorter operative times, fewer complications, and improved outcomes associated with the endoscopic technique.